Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Xencor reported $-57120000 in EBITDA for its fiscal quarter ending in March of 2023.

Ebitda Change
Alnylam Pharmaceuticals ALNY:US USD -135742000 38.56M
Amgen AMGN:US USD 3B 42M
Arrowhead Research ARWR:US USD 50.84M 90.27M
AstraZeneca AZN:LN USD 4.28B 965M
Biogen BIIB:US USD 686.7M 312.1M
Bristol-Myers Squibb BMY:US USD 5.43B 772M
GlaxoSmithKline GSK:LN GBP 2.56B 960M
J&J JNJ:US USD 9B 934.8M
MacroGenics MGNX:US USD -35443000 50.66M
Novartis NOVN:VX USD 4.72B 217M
Pfizer PFE:US USD 8.01B 683M
Regeneron Pharmaceuticals REGN:US USD 1.1B 195.4M
Roche Holding ROG:VX CHF 10.43B 3B
Seattle Genetics SGEN:US USD -136400000 297K
Xencor XNCR:US USD -57120000 16.69M